EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Value of the C‐ PLAN Index in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors

Yi Zhou, Li-Hua Yang, Jing Tang, Yuan-Ming Li, Ping Zhao, Zan Li iD

The Kaohsiung Journal of Medical Sciences · 2025

DOI: 10.1002/kjm2.70140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, 2025. Verfasst von Yi Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Guangyuan Central Hospital, Guangyuan, Sichuan, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated the prognostic value of the C‐PLAN index in advanced esophageal squamous cell carcinoma (ESCC) patients receiving immune checkpoint inhibitor (ICI) therapy. A retrospective analysis of 241 eligible patients treated during February 2020 to January 2023 was conducted. Based on the C‐PLAN index, calculated from lactate dehydrogenase (LDH), C‐reactive protein (CRP), performance status (PS), albumin (ALB), and derived neutrophil‐to‐lymphocyte ratio (dNLR), patients were categorized into Good (0–1 points) and Poor (2–5 points) groups. The Poor group exhibited more advanced clinical stages and larger tumor diameters (both p < 0.05). The Good group demonstrated a significantly higher objective response rate and disease control rate (both p < 0.05), lower progression/death incidence (both p < 0.001), and longer progression‐free survival and overall survival ( p < 0.001). Multifactorial Cox regression analysis revealed that PD‐L1 CPS < 10%, clinical stage IV, and high C‐PLAN score (2–5 points) were independent risk factors for disease progression or death following ICI therapy in patients with advanced ESCC. The C‐PLAN index effectively stratifies prognosis and optimizes therapeutic decision‐making for advanced ESCC. The C‐PLAN index serves as a prognostic factor, providing an objective basis for survival assessment and treatment plan optimization in advanced ESCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaHumansPrognosisMaleFemaleAgedMiddle AgedRetrospective StudiesC-Reactive ProteinNeoplasm StagingL-Lactate DehydrogenaseProgression-Free SurvivalNeutrophils

Stichwörter der Autor:innen

C‐PLAN indexdisease progressionesophageal squamous cell carcinomaimmune checkpoint inhibitorsprognosis

Substanzen

Immune Checkpoint InhibitorsC-Reactive ProteinL-Lactate Dehydrogenase

Autor:innen und Institutionen

  • Department of Gastroenterology, Guangyuan Central Hospital, Guangyuan, Sichuan, China.
  • Department of General Surgery, Guangyuan Hospital of Traditional Chinese Medicine, Guangyuan, Sichuan, China.

ORCID-Profile: Zan Li

Zitieren

APA

Zhou, Y., Yang, L. H., Tang, J., Li, Y. M., Zhao, P., & Li, Z. (2025). Prognostic Value of the C‐ PLAN Index in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.70140

Vancouver

Zhou Y, Yang LH, Tang J, Li YM, Zhao P, Li Z. Prognostic Value of the C‐ PLAN Index in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors. The Kaohsiung Journal of Medical Sciences. 2025. doi:10.1002/kjm2.70140

BibTeX
@article{Zhou2025,
  author = {Zhou, Yi and Yang, Li-Hua and Tang, Jing and Li, Yuan-Ming and Zhao, Ping and Li, Zan},
  title = {Prognostic Value of the C‐ PLAN Index in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors},
  journal = {The Kaohsiung Journal of Medical Sciences},
  year = {2025},
  doi = {10.1002/kjm2.70140}
}
Kostenlos starten →